Effects of treatment with growth hormone and somatostatin on efficacy of diammine [1,1-cyclobutane dicarboxylato (2-)-0,0']-(SP-4-2) in athymic rats with osteosarcoma.
OBJECTIVE
To determine the effect of exogenous growth hormone or somatostatin on chemotherapeutic efficacy in athymic (nude) rats with osteosarcoma.


METHODS
66 female athymic rats.


METHODS
Osteosarcoma was induced at an intratibial site. Rats were randomly allotted to 6 treatment groups. Rats were treated with saline (0.9% NaCl) solution alone, platinum, diammine [1,1-cyclobutane dicaboxylato (2-)-0,0']-(SP-4-2) (CBDCA; ie, carboplatin) plus saline solution, somatostatin alone, somatostatin plus CBDCA, growth hormone alone, or growth hormone plus CBDCA. Variables measured included estimated WBC count and percentage of neutrophils, plasma concentration of insulin-like growth factor I (IGF-I), body weight, tumor volume, weight of primary tumor, survival time, and distant metastasis at time of death.


RESULTS
Tumors formed at the injection sites in all rats. Treatment with growth hormone increased, and treatment with somatostatin decreased, plasma IGF-I concentration. Treatment with growth hormone or somatostatin altered CBDCA efficacy, as determined by evaluation of mean and median survival times. Metastatic pulmonary disease developed in 63 of 64 rats.


CONCLUSIONS
The technique used here reliably induced local osteosarcomas and metastatic pulmonary disease. Treatment with growth hormone and CBDCA or somatostatin may improve chemotherapeutic efficacy without increasing toxic effects. IMPLICATIONS FOR HUMAN MEDICINE: Results reported here may be useful in the study of osteosarcoma in humans.
Conzemius
M G
MG
Department of Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames 50010, USA.
Graham
J C
JC
Haynes
J S
JS
Graham
C A
CA
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001835:Body Weight; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016190:Carboplatin / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D013006:Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007958:Leukocyte Count / Q000187:drug effects / Q000662:veterinary; D009368:Neoplasm Transplantation; D009504:Neutrophils; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology; D011863:Radioimmunoassay; D011897:Random Allocation; D051381:Rats; D011923:Rats, Nude; D017207:Rats, Sprague-Dawley; D013004:Somatostatin / Q000494:pharmacology / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D016190:Carboplatin